calcitonin and Glomerulonephritis

To study possible correction of bone disorders (osteopenia, Ca/P-imbalance, bone pain, limited volume of indolent movements) which are still a serious complication associated with renal diseases and pathogenic therapy (steroids).. The bone disorders were treated in 10 uremic hemodialyzed patients (8 men, 2 women; group 1) with vitamin D3 (calcitriol made in Russia) + rhEPO (recormon; Boehringer Mannheim), in 15 patients (15 women, 0 men) with lupus-nephritis (group 2) with vitamin D3 (n = 5, group 2a) or miscalcic (Sandoz) (n = 10, group 2b), in 2 patients (2 men, 0 women) with glomerulonephritis (group 3) with vitamin D3 + miacalcic. Additionally all the patients received Ca salts. In groups 2 and 3 renal function was normal. The duration of the treatment was 3-6 months.. In all the groups we obtained an analgetic effect (attenuation of bone pain and more indolent movements), improvement of life quality, diminished need in analgetics, elevation of serum Ca level (p > 0.05).. Treatment of renal patients with bone affection with vitamin D3 and miacalcic has an analgetic effect, improves life quality.

Topics: Adult; Analgesics; Bone Diseases; Calcitonin; Calcium; Cholecalciferol; Drug Therapy, Combination; Erythropoietin; Female; Glomerulonephritis; Humans; Lupus Nephritis; Male; Middle Aged; Quality of Life; Recombinant Proteins; Renal Dialysis; Treatment Outcome; Uremia

The physiological role of calcitonin is still uncertain. Recently human calcitonin gene-related peptide, produced by alternative RNA processing from the calcitonin gene, was shown to have structural homology to salmon calcitonin and probably have a modulator function in the hypothalamus. In this study, salmon calcitonin was infused at a low dose (10 MRC units over 30 min) in seven patients with impaired renal function (51-Cr-EDTA clearance = 34.8 +/- 4.8 ml/min) in order to elucidate its effects on PRL secretion. The results show that salmon calcitonin at a subhypocalcaemic dose significantly suppresses PRL secretion by over 40% (P less than 0.01) and may be of therapeutic use in the treatment of gonadal dysfunction in chronic renal failure.

Topics: Adult; Calcitonin; Female; Glomerulonephritis; Humans; Hyperprolactinemia; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged